Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.94 USD
Change Today -0.36 / -15.65%
Volume 375.7K
SNGX On Other Exchanges
Symbol
Exchange
Berlin
OTC BB
As of 5:19 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Open
$2.25
Previous Close
$2.30
Day High
$2.25
Day Low
$1.89
52 Week High
06/24/15 - $2.95
52 Week Low
12/19/14 - $0.91
Market Cap
49.9M
Average Volume 10 Days
641.3K
EPS TTM
$-0.40
Shares Outstanding
25.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a late-stage biopharmaceutical company, engages in developing products to address unmet medical needs in the areas of inflammation, oncology, and biodefense. It operates through two segments, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation comprising pediatric Crohn’s disease and acute radiation enteritis, as well as innate defense regulator technology for the treatment of oral mucositis in head and neck cancer. This segment also develops SGX301, a photo-dynamic therapy for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment is developing RiVax, a ricin toxin vaccine candidate; VeloThrax, an anthrax vaccine candidate; OrbeShield, a gastrointestinal acute radiation syndrome therapeutic candidate; and SGX943, a melioidosis therapeutic candidate. These vaccine programs are supported by the company’s ThermoVax heat stabilization technology. Soligenix, Inc. has collaboration with Intrexon Corporation to develop and commercialize a human monoclonal antibody therapy (SGX101) to treat melioidosis. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

17 Employees
Last Reported Date: 03/27/15
Founded in 1987

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $527.0K
Acting Chief Financial Officer, Vice Presiden...
Total Annual Compensation: $232.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $362.0K
Compensation as of Fiscal Year 2014.

soligenix inc (SNGX) Key Developments

Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine

Soligenix, Inc. announced a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax™, licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax™ has been previously demonstrated to enhance thermostability of both ricin (RiVax™) and anthrax (VeloThrax™) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus (VSV) and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer's vaccine is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax™ may allow for a product that can avoid the need for cold-chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world.

Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Soligenix, Inc. reported earnings results for the first quarter ended March 31, 2015. The company's revenues for the quarter ended March 31, 2015 were $0.8 million as compared to $0.9 million for the first quarter of 2014. Revenues included contracts with the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in support of OrbeShield™ (oral beclomethasone 17,21-dipropionate or BDP) development for the treatment of gastrointestinal acute radiation syndrome (GI ARS) and a contract with NIAID to advance the development of RiVax™, its proprietary ricin toxin vaccine, in conjunction with its heat stabilization technology, ThermoVax™, as a medical countermeasure to prevent the effects of ricin exposure. The company's basic net loss was $4.6 million, or $0.19 per share, as compared to $3.3 million, or $0.17 per share, for the first quarter ended March 31, 2015 and 2014, respectively. Included in the net loss for the quarter ended March 31, 2015 and 2014 is a non-cash loss of $3.0 million and $1.7 million, respectively. This non-cash item reflects the increase in fair value of the liability related to warrants issued in connection with the company's June 25, 2013 registered public offering and is included in other income (expense).

Soligenix, Inc., Annual General Meeting, Jun 18, 2015

Soligenix, Inc., Annual General Meeting, Jun 18, 2015., at 09:00 US Eastern Standard Time. Location: Double Tree Hotel, 4355 US Route 1. Agenda: To elect six directors to serve until the next Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified; to approve 2015 Equity Incentive Plan; to ratify the appointment of EisnerAmper LLP as the company’s independent registered public accountants for the year ending December 31, 2015; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $1.94 USD -0.36

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies
 

Industry Analysis

SNGX

Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit www.soligenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.